Cancer Research Technology
Log in Register
Menu

PI3K-C2b – kinase-dead

Invented by Bart Vanhaesebroeck
Invented at Ludwig Institute for Cancer Research

Info

Catalogue Number 158398
Antigen/Gene or Protein Targets PIK3C2B
Model Knock-In
Production Details Knock-in mice in which the endogenous PIK3C2B/PI3K-C2beta PI3K gene is mutated so that it now encodes a PI3K-C2beta protein with the D1212A mutation in the ATP binding site, converting it to a kinase-dead PI3K-C2beta protein which is expressed at the same level as wild-type PI3K-C2beta. These mice have been backcrossed onto the B6 background.
Mouse Genetic Background/Cross History Backcrossed onto C57B6/J for more than 10 generations.
Research Area Cancer
Notes Homozygous mice are phenotypically normaland born at a normal Mendelian ratio, with no impact on organismal growth. Mice display enhanced insulin sensitivity and glucose tolerance, as well as protection against high-fat-diet-induced liver steatosis. (see PMID 26655903 for details). Heterozygous mice are phenotypically normal.

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Alliouachene et al. 2015. Cell Rep. 13(9):1881-94. PMID: 26655903.


Add a reference

References: 1 entry

Alliouachene et al. 2015. Cell Rep. 13(9):1881-94. PMID: 26655903.


Add a reference

Inventor Information